TrkA kinase inhibitors, compositions and methods thereof

1. A compound of formula I:

or a pharmaceutically acceptable salt thereof, wherein

B is selected from the group consisting of indazolyl, pyrazolopyrimidinyl, pyrazolopyridinonyl, and pyrazolopyridinyl, wherein when B is indazolyl it is substituted with 1 to 3 groups of Ra and when B is pyrazolopyrimidinyl, pyrazolopyridinonyl, and pyrazolopyridinyl B is optionally substituted with 1 to 3 groups of R a ;

R is selected from the group consisting of hydrogen, OH, —C 1-6 alkylOH, or —C 1-6 alkyl;

R 1 and R 5 are independently selected from the group consisting of hydrogen, CN, OH, C 1-6 alkyl, and halogen;

R 2 and R 4 are independently selected from the group consisting of hydrogen, halogen, C 1-4 haloalkyl, C1-6 alkyl, (CHR) n C 6-10 aryl and (CHR) n C 5-10 heterocycle, said alkyl, aryl, and heterocycle optionally substituted with 1 to 3 groups of R a , provided that at least one of R 2 and R 4 are is (CHR) n C 5-10 heterocycle,

R 3 is selected from the group consisting of C 1-4 haloalkyl, and —OC 1-4 haloalkyl;

R a is selected from the group consisting of CN, NO 2 , —C 1-4 haloalkyl, —OC 1-4 haloalkyl, —C 1-6 alkyl, —C 1-6 alkenyl, —C 1-6 alkynyl, —(CH 2 ) n C 3-6 cycloalkyl, —(CHR) n C 6-10 aryl, —(CHR) n C 4-10 heterocycle, —(CHR) n C(O)(CHR) n C 4-10 heterocycle, —O—(CH 2 ) n C 6-10 aryl, —O—(CH 2 ) n C 4-10 heterocycle, —O—, —(CH 2 ) n N(R d ) 2 , —(CH 2 ) n C(O)NH(CH 2 ) n C 4-10 heterocycle, SO 2 R d , SO 2 N(R d ) 2 , —C(O)CF 3 , COR, —(CH 2 ) n halo, —(CH 2 ) n NHC(c))R d , —(CH 2 ) n NHC(O)NHR d , —(CH 2 ) n NHC(O)OR d , —(CHR) n C(O))N(R d ) 2 , —O—C 1-6 alkyl, and —OH, said alkyl, cycloalkyl, aryl and heterocycle optionally substituted with 1 to 3 groups of R b , wherein when two R d groups are attached to a nitrogen atom they may combine with that nitrogen to from a 4-8 membered heterocycle that is optionally substituted with 1 to 3 groups of R f ;

R b is selected from the group consisting of —C 1-6 alkyl, —C 1-6 alkylOR, —C 1-4 haloalkyl, —(CH 2 ) n C 3-6 cycloalkyl, —(CH 2 ) n N(R d ) 2 , —(CH 2 ) n OR c , —O—, halogen, —CN, S(O)(NH)R g , —SO 2 R, —SO 2 N(R d ) 2 , —O—(CH 2 ) n C 4-10 heterocycle, —(CH 2 ) n C(O)N(R d ) 2 , —(CH 2 ) n NHC(O)R d , —C 1-6 alkylN(R d ) 2 , and halo, said cycloalkyl optionally substituted with 1 to 3 groups of R f , and wherein when two R d groups are attached to a nitrogen atom they may combine with that nitrogen to from a 4-8 membered heterocycle that is optionally substituted with 1 to 3 groups of R f ;

R c is selected from the group consisting of hydrogen, —C 1-6 alkylOR g , —C 1-4 haloalkyl and —C 1-6 alkyl;

R d is independently selected from the group consisting of hydrogen, —C 1-4 haloalkyl —C 1-6 alkyl, —(CH 2 ) n NR f C 4-10 heterocycle, —(CH 2 ) n C 3-6 cycloalkyl, and —(CH 2 ) n C4-10heterocycle said alkyl, cycloalkyl and heterocycle optionally substituted with 1 to 3 groups of Rf;

R f is selected from the group consisting of hydrogen, OR c , CN, —N(R c ) 2 , C(O)N(R g ) 2 , C(O)C 1-6 alkyl, —SO 2 R g , —O—, —C 1-6 alkylSO 2 R g , —C 1-6 alkylOR g , —C 1-6 alkylN(R g ) 2 ,

R g is selected from the group consisting of hydrogen, and —C 1-6 alkyl; and

n represents 0-6.

2. The compound according to claim 1 wherein B is unsubstituted or substituted and pyrazolopyridinyl, or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 wherein B is unsubstituted or substituted pyrazolopyrimidinyl, or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 1 wherein one of R 2 and R 4 is hydrogen and the other is (CHR) n C 5-10 heterocycle, said heterocycle optionally substituted with 1 to 3 groups of R a and R 3 is selected from the group consisting of CF 3 , OCF 3 , or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 4 wherein the optionally substituted heterocycle of R 2 and R 4 is a five or six membered ring containing one or more heteroatoms at least one of which is nitrogen, or a pharmaceutically acceptable salt thereof.

6. The compound according to claim 1 wherein one of R 2 and R 4 is hydrogen and the other is selected from the group consisting of optionally substituted pyrazolyl, pyridyl, thiazolyl, oxazolyl, pyrimidinyl, pyridazinyl, pyrazinyl, thiadiazolyl, oxadiazolyl and triazolyl, or a pharmaceutically acceptable salt thereof.

7. The compound according to claim 6 wherein the heterocycle is optionally substituted pyrazolyl, or a pharmaceutically acceptable salt thereof.

8. The compound according to claim 1 wherein R 3 is selected from the group consisting of CF 3 , OCF 3 , or a pharmaceutically acceptable salt thereof.

9. The compound according to claim 1 of formula I wherein B is represented by structural formulas (a), (b), (c), (d), (e), and (f):

wherein:

R 6 represents (CH 2 ) n C 6-10 aryl, or (CH 2 ) n C 5-10 heterocycle, said aryl, and heterocycle optionally substituted with 1 to 3 groups of R a ; and

R 7 , R 8 , R 9 and R 10 independently represent hydrogen, halogen, CN, —O—, C 1-6 alkyl, (CH 2 ) n N(R) 2 , C(CH 3 ) 2 N(R) 2 , C(CF 3 ) 2 N(R) 2 , C 1-4 haloalkyl, (CH 2 ) n C(O)N(R) 2 , (CH 2 ) n C 3-10 cyclopropyl, (CH 2 ) n C 6-10 aryl, or (CH 2 ) n C 5-10 heterocycle, said alkyl, aryl, and heterocycle optionally substituted with 1 to 3 groups of R a , or a pharmaceutically acceptable salt thereof.

10. The compound according to claim 9 wherein B is pyrazolopyridinyl represented by structural formula II:

or a pharmaceutically acceptable salt thereof,

wherein one of Ya, Yb, Yc, and Yd is nitrogen and the others are —CH—.

11. The compound according to claim 10 wherein R 6 is unsubstituted or substituted phenyl, thiazolyl, pyrazolyl, pyridyl, isoxazolyl, oxazolyl, or pyrimidinyl, R 8 and R 9 are independently selected from hydrogen, halogen, CN, CH 2 OH, C(O)N(R) 2 , CH(CH 3 )OH, C(CH 3 ) 2 OH, optionally substituted C 1-6 alkyl, phenyl, pyrazolyl, isoxazolyl, oxazolyl, (CH 2 ) n azetidinyl, and C(O)NHazetidinyl, and R 7 and R 10 are independently selected from hydrogen, C 1-6 alkyl, C(O)NH 2 , and halogen, said alkyl optionally substituted with 1 to 3 groups of R b , or a pharmaceutically acceptable salt thereof.

12. The compound of formula III according to claim 1 :

or a pharmaceutically acceptable salt thereof,

wherein: R 6 is unsubstituted or substituted phenyl, thiazolyl, pyrazolyl, pyridyl, isoxazolyl, oxazolyl or pyrimidinyl, R 8 and R 9 are independently selected from hydrogen, halogen, CN, CH 2 OH, C(O)N(R) 2 , CH(CH 3 )OH, C(CH 3 ) 2 OH, optionally substituted C 1-6 alkyl, phenyl, pyrazolyl, isoxazolyl, oxazolyl, (CH 2 ) n azetidinyl, and C(O)NHazetidinyl, R 7 and R 10 are independently selected from hydrogen, C 1-6 alkyl, C(O)NH 2 , and halogen, said alkyl optionally substituted with 1 to 3 groups of R b , R 3 is selected from the group consisting of CF 3 , and OCF 3 , and one of R 2 and R 4 is hydrogen and the other is (CHR) n C 5-10 heterocycle, said heterocycle optionally substituted with 1 to 3 groups of R a .

13. The compound according to claim 12 wherein R 1 and R 5 are both hydrogen or one is hydrogen and the other halogen, R 3 is OCF 3 , or CF 3 , one of R 2 and R 4 is hydrogen and the other is an optionally substituted (CHR) n C 5-10 heterocycle that is a five or six membered ring containing one or more heteroatoms at least one of which is nitrogen, or a pharmaceutically acceptable salt thereof.

14. The compound according to claim 13 wherein the optionally substituted heterocycle of R 2 and R 4 is selected from the group consisting of pyrazolyl, pyridyl, thiazolyl, oxazolyl, pyrimidinyl, pyridazinyl, pyrazinyl, thiadiazolyl, oxadiazolyl and triazolyl, or a pharmaceutically acceptable salt thereof.

15. The compound according to claim 12 wherein one of R 2 and R 4 is hydrogen and the other is pyrazolyl, R 6 is optionally substituted phenyl and R 3 is CF 3 , or a pharmaceutically acceptable salt thereof.

16. A compound which is selected from the group consisting of

2-Fluoro-N-(2-phenyl-2H-pyrazolo[4,3-b]pyridin-3-yl)-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide,

2-Fluoro-N-(5-oxo-2-phenyl-4,5-dihydro-2H-pyrazolo[4,3-b]pyridin-3-yl)-5-(pyrimidin-2-yl)-4-(trifluoromethyl)benzamide,

2-Fluoro-N-(2-(3-(hydroxymethyl)phenyl)-2H-pyrazolo[4,3-b]pyridin-3-yl)-5-(pyrimidin-2-yl)-4-(trifluoromethyl)benzamide,

N-(5-Cyano-2-phenyl-2H-indazol-3-yl)-3-(1-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)benzamide,

2-Fluoro-5-(1-methyl-1H-pyrazol-3-yl)-N-(2-phenyl-2H-pyrazolo[4,3-b]pyridin-3-yl)-4-(trifluoromethyl)benzamide,

2-Fluoro-5-(1-methyl-1H-pyrazol-3-yl)-N-(2-phenyl-2H-pyrazolo[3,4-b]pyridin-3-yl)-4-(trifluoromethyl)benzamide,

2-Fluoro-5-(1-methyl-1H-pyrazol-3-yl)-N-[2-phenyl-5-(trifluoromethyl)-2H-indazol-3-yl]-4-(trifluoromethyl)benzamide,

2-Fluoro-N-(5-methoxy-2-phenyl-2H-pyrazolo[4,3-b]pyridin-3-yl)-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide,

N-(2-{3-[(Acetylamino)methyl]phenyl}-2H-pyrazolo[4,3-b]pyridin-3-yl)-2-fluoro-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide,

N-(5-(Hydroxymethyl)-2-phenyl-2H-indazol-3-yl)-3-(1-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)benzamide,

2-Fluoro-N-(5-(hydroxymethyl)-2-phenyl-2H-pyrazolo[3,4-c]pyridin-3-yl)-5-(pyrimidin-2-yl)-4-(trifluoromethyl)benzamide

2-Fluoro-N[5-(hydroxymethyl)-2-phenyl-2H-indazol-3-yl]-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide,

2-Fluoro-N[6-(hydroxymethyl)-2-phenyl-2H-indazol-3-yl]-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide,

2-Fluoro-N-[6-(hydroxymethyl)-2-phenyl-2H-indazol-3-yl]-5-(1H-pyrazol-3-yl)-4-(trifluoromethyl)benzamide,

2-Fluoro-N-[5-(hydroxymethyl)-2-(5-methyl-1H-pyrazol-3-yl)-2H-indazol-3-yl]-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide,

2-Chloro-N-[6-(hydroxymethyl)-2-phenyl-2H-indazol-3-yl]-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide,

2-Chloro-N-[5-(hydroxymethyl)-2-phenyl-2H-pyrazolo[4,3-b]pyridin-3-yl]-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide,

2-Fluoro-N-[5-(hydroxymethyl)-2-phenyl-2H-pyrazolo[3,4-c]pyridin-3-yl]-5-(1-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)benzamide,

(R and S)-2-Fluoro-N-(6-(1-hydroxyethyl)-2-phenyl-2H-indazol-3-yl)-5-(pyrimidin-2-yl)-4-(trifluoromethyl)benzamide, isomers A and B,

2-Fluoro-N-(6-(1-hydroxyethyl)-2-phenyl-2H-pyrazolo[4,3-b]pyridin-3-yl)-5-(1H-pyrazol-3-yl)-4-(trifluoromethyl)benzamide, isomers A and B,

(R or S)—N-[5-(1-Hydroxyethyl)-2-phenyl-2H-indazol-3-yl]-3-(1-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)benzamide, isomer A

(R or S)—N-[5-(1-Hydroxyethyl)-2-phenyl-2H-indazol-3-yl]-3-(1-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)benzamide, isomer B,

(R or S)-2-Fluoro-N-(5-(1-hydroxyethyl)-2-phenyl-2H-indazol-3-yl)-5-(pyrimidin-2-yl)-4-(trifluoromethyl)benzamide, isomer A,

(R or S)-2-Fluoro-N-(5-(1-hydroxyethyl)-2-phenyl-2H-indazol-3-yl)-5-(pyrimidin-2-yl)-4-(trifluoromethyl)benzamide, isomer B,

(R or S)-2-Fluoro-N-[5-(1-hydroxyethyl)-2-phenyl-2H-pyrazolo[4,3-b]pyridin-3-yl]-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide, isomer A,

(R or S)-2-Fluoro-N-[5-(1-hydroxyethyl)-2-phenyl-2H-pyrazolo[4,3-b]pyridin-3-yl]-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide, isomer B,

(R or S)-2-Fluoro-N-[6-(1-hydroxyethyl)-2-phenyl-2H-pyrazolo[4,3-b]pyridin-3-yl]-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide, isomer A,

(R or S)-2-Fluoro-N-[6-(1-hydroxyethyl)-2-phenyl-2H-pyrazolo[4,3-b]pyridin-3-yl]-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide, isomer B,

(R or S)-2-Fluoro-N-[5-(1-hydroxyethyl)-2-phenyl-2H-pyrazolo[4,3-b]pyridin-3-yl]-5-(1H-pyrazol-3-yl)-4-(trifluoromethyl)benzamide, isomer A,

(R or S)-2-Fluoro-N-[5-(1-hydroxyethyl)-2-phenyl-2H-pyrazolo[4,3-b]pyridin-3-yl]-5-(1H-pyrazol-3-yl)-4-(trifluoromethyl)benzamide, isomer B,

(R or S)-2-Fluoro-N-[6-(1-hydroxyethyl)-2-phenyl-2H-pyrazolo[4,3-b]pyridin-3-yl]-5-(1-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)benzamide, isomer A,

(R or S)-2-Fluoro-N-[6-(1-hydroxyethyl)-2-phenyl-2H-pyrazolo[4,3-b]pyridin-3-yl]-5-(1-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)benzamide, isomer B,

(R or S)-2-Chloro-N-[6-(1-hydroxyethyl)-2-phenyl-2H-pyrazolo[4,3-b]pyridin-3-yl]-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide, isomer A,

(R or S)-2-Chloro-N-[6-(1-hydroxyethyl)-2-phenyl-2H-pyrazolo[4,3-b]pyridin-3-yl]-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide, isomer B,

(R or S)-2-Chloro-N-[6-(1-hydroxyethyl)-2-phenyl-2H-indazol-3-yl]-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide, isomer A,

(R or S)-2-Chloro-N-[6-(1-hydroxyethyl)-2-phenyl-2H-indazol-3-yl]-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide, isomer B,

(R or S)-2-fluoro-N-[6-(1-hydroxyethyl)-2-phenyl-2H-pyrazolo[4,3-c]pyridin-3-yl]-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide, isomer A,

2-Fluoro-N-(6-(2-hydroxypropan-2-yl)-2-phenyl-2H-pyrazolo[4,3-b]pyridin-3-yl)-5-(pyrimidin-2-yl)-4-(trifluoromethyl)benzamide

2-Fluoro-N-(6-(2-hydroxypropan-2-yl)-2-phenyl-2H-pyrazolo[4,3-b]pyridin-3-yl)-5-(1-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)benzamide,

2-Fluoro-N-(5-(2-hydroxypropan-2-yl)-2-phenyl-2H-indazol-3-yl)-5-(pyrimidin-2-yl)-4-(trifluoromethyl)benzamide,

2-Fluoro-N-(5-(2-hydroxypropan-2-yl)-2-phenyl-2H-pyrazolo[4,3-d]pyrimidin-3-yl)-5-(1-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)benzamide,

2-Fluoro-N-(5-(2-hydroxypropan-2-yl)-2-phenyl-2H-indazol-3-yl)-5-(pyrimidin-2-yl)-4-(trifluoromethyl)benzamide,

2-Fluoro-N-[5-(1-hydroxy-1-methylethyl)-2-phenyl-2H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide,

2-Chloro-N-[6-(1-hydroxy-1-methylethyl)-2-phenyl-2H-indazol-3-yl]-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide,

2-Fluoro-N-[6-(1-hydroxy-1-methylethyl)-2-phenyl-2H-pyrazolo[4,3-b]pyridin-3-yl]-5-(1H-pyrazol-3-yl)-4-(trifluoromethyl)benzamide,

N-[6-(1-Hydroxy-1-methylethyl)-2-phenyl-2H-pyrazolo[4,3-b]pyridin-3-yl]-3-(1-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)benzamide,

2-Chloro-N-[6-(1-hydroxy-1-methylethyl)-2-phenyl-2H-pyrazolo[4,3-b]pyridin-3-yl]-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide,

2-Fluoro-N-(5-(1-hydroxycyclopropyl)-2-phenyl-2H-indazol-3-yl)-5-(pyrimidin-2-yl)-4-(trifluoromethyl)benzamide,

N-[5-(1-Hydroxycyclopropyl)-2-phenyl-2H-indazol-3-yl]-3-(1-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)benzamide,

(R or S)-2-Fluoro-N-{2-phenyl-6-[(1S)-2,2,2-trifluoro-1-hydroxyethyl]-2H-indazol-3-yl}-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide, isomers A and B,

(R or S)-2-Fluoro-N-(2-phenyl-5-(2,2,2-trifluoro-1-hydroxyethyl)-2H-indazol-3-yl)-5-(pyrimidin-2-yl)-4-(trifluoromethyl)benzamide, isomer A,

(R or S)-2-Fluoro-N-{2-phenyl-6-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]-2H-indazol-3-yl}-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide, isomer B,

(R or S)—N-[6-(2,2-Difluoro-1-hydroxyethyl)-2-phenyl-2H-indazol-3-yl]-2-fluoro-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide, isomer A,

(R or S)—N-[6-(2,2-Difluoro-1-hydroxyethyl)-2-phenyl-2H-indazol-3-yl]-2-fluoro-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide, isomer B,

(R or S)—N-[5-(2,2-Difluoro-1-hydroxyethyl)-2-phenyl-2H-indazol-3-yl]-2-fluoro-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide, isomer A,

(R or S)—N-[5-(2,2-Difluoro-1-hydroxyethyl)-2-phenyl-2H-indazol-3-yl]-2-fluoro-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide, isomer B,

2-Fluoro-N-(6-(2-hydroxyethyl)-2-phenyl-2H-indazol-3-yl)-5-(pyrimidin-2-yl)-4-(trifluoromethyl)benzamide,

2-Fluoro-N-[5-(2-hydroxyethyl)-2-phenyl-2H-indazol-3-yl]-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide,

N-(6-(1,2-Dihydroxypropan-2-yl)-2-phenyl-2H-indazol-3-yl)-3-(1-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)benzamide, isomers A and B,

(R or S)-2-Chloro-N-[6-(1,2-dihydroxyethyl)-2-phenyl-2H-pyrazolo[4,3-b]pyridin-3-yl]-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide, isomer A,

(R or S)-2-Chloro-N-[6-(1,2-dihydroxyethyl)-2-phenyl-2H-pyrazolo[4,3-b]pyridin-3-yl]-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide, isomer B,

N-(6-(Aminomethyl)-2-phenyl-2H-pyrazolo[4,3-b]pyridin-3-yl)-2-fluoro-5-(pyrimidin-2-yl)-4-(trifluoromethyl)benzamide,

N-(6-((Dimethylamino)methyl)-2-phenyl-2H-indazol-3-yl)-2-fluoro-5-(pyrimidin-2-yl)-4-(trifluoromethyl)benzamide,

N-{5-[(Dimethylamino)methyl]-2-phenyl-2H-indazol-3-yl}-3-(1-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)benzamide,

(R or S)—N-{6-[1-Aminoethyl]-2-phenyl-2H-indazol-3-yl}-2-fluoro-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide,

(R or S)—N-{6-[1-Aminoethyl]-2-phenyl-2H-indazol-3-yl}-2-fluoro-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide,

N-[6-(Aminomethyl)-2-phenyl-2H-indazol-3-yl]-2-fluoro-5-(1-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)benzamide,

2-Fluoro-N-(6-{[(2-hydroxyethyl)amino]methyl}-2-phenyl-2H-indazol-3-yl)-5-(1-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)benzamide,

3-(2-Fluoro-5-(pyrimidin-2-yl)-4-(trifluoromethyl)benzamido)-2-phenyl-2H-indazole-6-carboxamide,

3-(2-Fluoro-5-(1-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)benzamido)-2-phenyl-2H-indazole-6-carboxamide,

3-(2-Fluoro-5-(pyrimidin-2-yl)-4-(trifluoromethyl)benzamido)-2-phenyl-2H-pyrazolo[4,3-b]pyridine-6-carboxamide

3-(2-Fluoro-5-(pyrimidin-2-yl)-4-(trifluoromethyl)benzamido)-2-phenyl-2H-pyrazolo[4,3-c]pyridine-6-carboxamide,

3-(2-Fluoro-5-(1-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)benzamido)-2-(o-tolyl)-2H-indazole-6-carboxamide,

3-({[2-Fluoro-5-(1H-pyrazol-3-yl)-4-(trifluoromethyl)phenyl]carbonyl}amino)-2-phenyl-2H-indazole-6-carboxamide,

3-({[3-(1-Methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)phenyl]carbonyl}amino)-2-phenyl-2H-indazole-5-carboxamide,

3-({[2-Fluoro-5-pyrimidin-2-yl-4-(trifluoromethyl)phenyl]carbonyl}amino)-2-phenyl-2H-pyrazolo[4,3-b]pyridine-5-carboxamide,

3-({[2-Fluoro-5-pyridin-2-yl-4-(trifluoromethyl)phenyl]carbonyl}amino)-2-phenyl-2H-indazole-6-carboxamide,

3-({[3-(1-Methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)phenyl]carbonyl}amino)-2-phenyl-2H-indazole-6-carboxamide,

3-({[2-Chloro-5-pyridin-2-yl-4-(trifluoromethyl)phenyl]carbonyl}amino)-2-phenyl-2H-indazole-6-carboxamide,

3-({[2-Fluoro-5-pyridin-2-yl-4-(trifluoromethyl)phenyl]carbonyl}amino)-2-phenyl-2H-pyrazolo[4,3-b]pyridine-6-carboxamide,

3-({[2-Chloro-5-pyridin-2-yl-4-(trifluoromethyl)phenyl]carbonyl}amino)-2-phenyl-2H-pyrazolo[4,3-b]pyridine-6-carboxamide,

3-({[3-(1-Methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)phenyl]carbonyl}amino)-2-phenyl-2H-pyrazolo[4,3-b]pyridine-6-carboxamide,

3-({[2-Fluoro-5-(1-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)phenyl]carbonyl}amino)-2-phenyl-2H-pyrazolo[4,3-b]pyridine-6-carboxamide,

2-Phenyl-3-({[3-pyrimidin-2-yl-4-(trifluoromethyl)phenyl]carbonyl}amino)-2H-pyrazolo[4,3-b]pyridine-6-carboxamide,

3-({[2-Fluoro-5-pyrimidin-2-yl-4-(trifluoromethyl)phenyl]carbonyl}amino)-2-phenyl-2H-indazole-7-carboxamide,

3-({[2-Chloro-5-pyrimidin-2-yl-4-(trifluoromethyl)phenyl]carbonyl}amino)-N-(2-hydroxyethyl)-2-phenyl-2H-indazole-6-carboxamide,

3-({[2-Fluoro-5-pyrimidin-2-yl-4-(trifluoromethyl)phenyl]carbonyl}amino)-2-(2-methylphenyl)-2H-pyrazolo[4,3-b]pyridine-6-carboxamide,

3-({[2-Fluoro-5-pyrimidin-2-yl-4-(trifluoromethyl)phenyl]carbonyl}amino)-N-(2-hydroxyethyl)-2-phenyl-2H-indazole-6-carboxamide,

3-({[2-Fluoro-5-pyrimidin-2-yl-4-(trifluoromethyl)phenyl]carbonyl}amino)-2-(2-methylphenyl)-2H-indazole-6-carboxamide,

N-(6-(2-Amino-2-oxoethyl)-2-phenyl-2H-indazol-3-yl)-2-fluoro-5-(pyrimidin-2-yl)-4-(trifluoromethyl)benzamide,

N-(7-(2-Amino-2-oxoethyl)-2-phenyl-2H-indazol-3-yl)-2-fluoro-5-(1-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)benzamide,

2-Fluoro-N-{6-[2-(methylamino)-2-oxoethyl]-2-phenyl-2H-indazol-3-yl}-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide,

N-[6-(2-Amino-2-oxoethyl)-2-phenyl-2H-pyrazolo[4,3-b]pyridin-3-yl]-2-chloro-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide,

2-Fluoro-N-(6-((2-hydroxyacetamido)methyl)-2-phenyl-2H-indazol-3-yl)-5-(pyrimidin-2-yl)-4-(trifluoromethyl)benzamide,

N-(7-((2,5-dioxoimidazolidin-1-yl)methyl)-2-phenyl-2H-pyrazolo[4,3-b]pyridin-3-yl)-2-fluoro-5-(1-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)benzamide,

(R)—N-(6-(1-Amino-2,2,2-trifluoroethyl)-2-phenyl-2H-indazol-3-yl)-3-(1-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)benzamide,

(S)—N-(6-(1-Amino-2,2,2-trifluoroethyl)-2-phenyl-2H-indazol-3-yl)-3-(1-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)benzamide,

(R and S)-2-Fluoro-N-(2-phenyl-6-(pyrrolidin-2-yl)-2H-indazol-3-yl)-5-(pyrimidin-2-yl)-4-(trifluoromethyl)benzamide, isomers A and B,

or a pharmaceutically acceptable salt thereof.

17. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

18. A method of treating a disease or disorder selected from the group consisting of pain, inflammation, and cancer in a human patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

19. A compound which is (R or S)-2-fluoro-N-(5-(1-hydroxyethyl)-2-phenyl-2H-indazol-3-yl)-5-(pyrimidin-2-yl)-4-(trifluoromethyl)benzamide, isomer A or B, or a pharmaceutically acceptable salt thereof.

20. A compound which is (R or S)-2-fluoro-N-[5-(1-hydroxyethyl)-2-phenyl-2H-pyrazolo[4,3]pyridin-3-yl]-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide, isomer A or B, or a pharmaceutically acceptable salt thereof.

21. A compound which is (R or S)-2-fluoro-N-[6-(1-hydroxyethyl)-2-phenyl-2H-pyrazolo[4,3]pyridin-3-yl]-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide, Isomer A or B, or a pharmaceutically acceptable salt thereof.

22. A compound which is 2-Fluoro-N-(6-(2-hydroxypropan-2-yl)-2-phenyl-2H-pyrazolo[4,3-b]pyridin-3-yl)-5-(pyrimidin-2-yl)-4-(trifluoromethyl)benzamide, or a pharmaceutically acceptable salt thereof.

23. A compound which is 2-Fluoro-N-(6-(2-hydroxypropan-2-yl)-2-phenyl-2H-pyrazolo[4,3-b]pyridin-3-yl)-5-(1-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)benzamidem or a pharmaceutically acceptable salt thereof.

24. A compound which is 2-Fluoro-N-(5-(2-hydroxypropan-2-yl)-2-phenyl-2H-indazol-3-yl)-5-(pyrimidin-2-yl)-4-(trifluoromethyl)benzamide, or a pharmaceutically acceptable salt thereof.